BioCentury | Jun 4, 2020
Emerging Company Profile

Hayden’s fifth venture, neuro-focused Prilenia, raises $62.5M in Forbion-led A round

Serial entrepreneur Michael Hayden is taking the helm as CEO of Prilenia as it readies for a pair of studies next half that could show whether pridopidine can slow progression of neurodegenerative diseases more effectively...
BioCentury | May 14, 2012
Strategy

Teva: No more silos

Teva Pharmaceutical Industries Ltd. 's new CSO and president of global R&D, Michael Hayden, plans to break down the silos housing generics and branded R&D with the aim of improving both businesses while better serving...
BC Extra | May 9, 2012
Company News

Teva names Hayden CSO

Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) hired Michael Hayden as CSO and president of global R&D. Hayden is currently a professor of medical genetics at the University of British Columbia and is Canada Research Chair in...
BioCentury | Sep 11, 2006
Strategy

MediGene chronicles

MediGene chronicles MediGene chroniclesSelected events tracked against MediGene’s weekly stock price (FSE:MDG). Y-axis = logarithmic scale A. 6/30/00 - Raises E125.4M ($117.4M) in an IPO. At that time, MDG was focused on developing therapeutics for cardiovascular...
BioCentury | Sep 11, 2006
Strategy

Biotech accumulators

It is becoming increasingly clear that investors in the European biotech sector are becoming much more discerning. No longer is it enough to have a promising clinical candidate to attract finance. Investors are backing companies...
BC Week In Review | Sep 22, 2003
Company News

Oncolytics scientific advisory board update

Oncolytics Biotech Inc. (TSE:ONC; ONCY), Calgary, Alberta   Business: Cancer   Appointed: Ramon Alemany, director of the Gene and Viral Therapy Group at the Institut Catala d'Oncologia, Barcelona; Richard Gorlick, director of the Pediatric Sarcoma...
BC Week In Review | Sep 10, 2001
Company News

MediGene, Children's Hospital deal

MDG expanded its exclusive license with the hospital for herpes simplex virus amplicon technology in neurological indications. As expanded, the license includes all other indications including cancer and cardiovascular areas. MDG said it will look...
BC Extra | Sep 6, 2001
Company News

MediGene expands amplicon license

Cancer and cardiovascular company MediGene (NMarkt:MDG) expanded its exclusive license with the Children's Hospital (Boston, Mass.) for the herpes simplex virus amplicon technology in neurological indications. As expanded, the license now includes all other indications...
BC Week In Review | Apr 9, 2001
Company News

Cell Genesys management update

Cell Genesys Inc. (CEGE), Foster City, Calif.   Business: Gene/Cell therapy, Neurological   Hired: Jeffrey Ostrove as president and COO of CEGE's Ceregene Inc. majority owned subsidiary, formerly COO at NeuroVir Therapeutics Inc.  ...
BC Week In Review | Mar 12, 2001
Clinical News

G207 engineered herpes simplex virus: Phase I

MDG published in Gene Therapy that G207 was well tolerated in a U.S./U.K. Phase I trial in 21 patients with recurrent, progressive malignant glioma who were radiation- and chemotherapy experienced. The company said that 10...
Items per page:
1 - 10 of 27
BioCentury | Jun 4, 2020
Emerging Company Profile

Hayden’s fifth venture, neuro-focused Prilenia, raises $62.5M in Forbion-led A round

Serial entrepreneur Michael Hayden is taking the helm as CEO of Prilenia as it readies for a pair of studies next half that could show whether pridopidine can slow progression of neurodegenerative diseases more effectively...
BioCentury | May 14, 2012
Strategy

Teva: No more silos

Teva Pharmaceutical Industries Ltd. 's new CSO and president of global R&D, Michael Hayden, plans to break down the silos housing generics and branded R&D with the aim of improving both businesses while better serving...
BC Extra | May 9, 2012
Company News

Teva names Hayden CSO

Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) hired Michael Hayden as CSO and president of global R&D. Hayden is currently a professor of medical genetics at the University of British Columbia and is Canada Research Chair in...
BioCentury | Sep 11, 2006
Strategy

MediGene chronicles

MediGene chronicles MediGene chroniclesSelected events tracked against MediGene’s weekly stock price (FSE:MDG). Y-axis = logarithmic scale A. 6/30/00 - Raises E125.4M ($117.4M) in an IPO. At that time, MDG was focused on developing therapeutics for cardiovascular...
BioCentury | Sep 11, 2006
Strategy

Biotech accumulators

It is becoming increasingly clear that investors in the European biotech sector are becoming much more discerning. No longer is it enough to have a promising clinical candidate to attract finance. Investors are backing companies...
BC Week In Review | Sep 22, 2003
Company News

Oncolytics scientific advisory board update

Oncolytics Biotech Inc. (TSE:ONC; ONCY), Calgary, Alberta   Business: Cancer   Appointed: Ramon Alemany, director of the Gene and Viral Therapy Group at the Institut Catala d'Oncologia, Barcelona; Richard Gorlick, director of the Pediatric Sarcoma...
BC Week In Review | Sep 10, 2001
Company News

MediGene, Children's Hospital deal

MDG expanded its exclusive license with the hospital for herpes simplex virus amplicon technology in neurological indications. As expanded, the license includes all other indications including cancer and cardiovascular areas. MDG said it will look...
BC Extra | Sep 6, 2001
Company News

MediGene expands amplicon license

Cancer and cardiovascular company MediGene (NMarkt:MDG) expanded its exclusive license with the Children's Hospital (Boston, Mass.) for the herpes simplex virus amplicon technology in neurological indications. As expanded, the license now includes all other indications...
BC Week In Review | Apr 9, 2001
Company News

Cell Genesys management update

Cell Genesys Inc. (CEGE), Foster City, Calif.   Business: Gene/Cell therapy, Neurological   Hired: Jeffrey Ostrove as president and COO of CEGE's Ceregene Inc. majority owned subsidiary, formerly COO at NeuroVir Therapeutics Inc.  ...
BC Week In Review | Mar 12, 2001
Clinical News

G207 engineered herpes simplex virus: Phase I

MDG published in Gene Therapy that G207 was well tolerated in a U.S./U.K. Phase I trial in 21 patients with recurrent, progressive malignant glioma who were radiation- and chemotherapy experienced. The company said that 10...
Items per page:
1 - 10 of 27